Medicenna Therapeutics

Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and commercialization of novel, highly selective IL-2, IL-4, and IL-13 supercytokines as well as first-in-class Empowered Cytokines (ECs) for the treatment of cancer. Medicenna's proprietary technology platform supports a unique multi-faceted therapeutic paradigm that can precisely deliver potent cell-killing agents to cancer while actively transforming the immune-suppressive tumor microenvironment without harming healthy cells.